ACC 2026: Lorundrostat lowers BP but raises hyperkalemia risk

At the 2026 ACC Scientific Session in New Orleans, Brazilian investigators presented a meta-analysis of three placebo-controlled trials (1,060 patients) assessing lorundrostat’s blood pressure and safety effects in uncontrolled hypertension.